Art. -Nr.: HY-N0747

Oxypeucedanin

Kundenbewertung

Based on 1 Customer Validation

Oxypeucedanin is a furanocoumarin derivative found in Angelica dahurica. Oxypeucedanin is an orally active PI3K/AKT/NF-κB, MAPK, and ROS inhibitor. Oxypeucedanin induces cell cycle arrest and apoptosis. Oxypeucedanin inhibits hKv1.5 channel currents (IC₅₀: 76 nM). Oxypeucedanin exhibits anticancer, anti-inflammatory, antioxidant and antiarrhythmic activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.50%
CAS. Nr.: 737-52-0
Formel: C₁₆H₁₄O₅
Molecular Weight:286.28

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Oxypeucedanin Chemical Structure

CAS. Nr.: 737-52-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: HKv1.5 current; apoptosis^[1]

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle COX Isoform-spezifische Produkte anzeigen :

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle JNK Isoform-spezifische Produkte anzeigen :

In Vitro

oxypeucedanin (1-1000 nM) inhibits hKv1.5 channel currents expressed in the mouse Ltk^- cell lines in a concentration-dependent manner (IC₅₀: 76 nM)^[1].
oxypeucedanin (0.1-1 μM) prolongs the action potential duration (APD) of rat atrial and ventricular myocytes in a concentration-dependent manner^[1].
Oxypeucedanin (25-100 μM, 24-72 h) inhibits the viability of human prostate cancer DU145 cells and induces apoptosis in a time- and dose-dependent manner^[2].
Oxypeucedanin (25-100 μM, 24-48 h) induces G2-M arrest in DU145 cell cycle progression in a dose-dependent manner^[2].
Oxypeucedanin (6.25-12.5 μM, 7-13 h) inhibits the expression of inflammatory factors IL-6, IL-1β, TNF-α, iNOS, COX-2 and the production of ROS in RAW264.7 cells^[3].
Oxypeucedanin (6.25-12.5 μM, 2 h) inhibits the PI3K/AKT/NF-κB and MAPK signaling pathways in RAW264.7 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

DU145 cells
Concentration:

25, 50 and 100 μM
Incubation Time:

24, 48 and 72 h
Result:

Inhibited cell growth.
Induced cell death.

Western Blot Analysis^[2]

Cell Line:

DU145 cells
Concentration:

25, 50 and 100 μM
Incubation Time:

24, 48 and 72 h
Result:

Decreased the protein levels of Cdc-25C, Cyclin A, Cyclin B1 and Cdc-2.
Increased the protein levels of Chk1, Chk2, cleaved caspase-3 and cleaved PARP.

Western Blot Analysis^[3]

Cell Line:

RAW264.7 cells
Concentration:

6.25 and 12.5 μM
Incubation Time:

2, 13 h
Result:

Decreased the protein levels of iNOS and COX-2.
Inhibited the phosphorylation levels of AKT, P65, P38, ERK1/2 and JNK proteins and the ubiquitination degradation of IκB proteins.

RT-PCR^[3]

Cell Line:

RAW264.7 cells
Concentration:

6.25 and 12.5 μM
Incubation Time:

7 h
Result:

Down-regulated the mRNA levels of inflammatory factors iNOS, COX-2, IL-6, IL-1β, and TNF-α.

Parmacokinetics

Species	Dose	Route	Plasma Concentration	AUC	MRT	T_max	Bioavailability
Rat^[5]	10 mg/kg	i.v.	1662.94 μg/L	1.28 mg·h/L	0.80 h	/	/
Rat^[5]	2.5 mg/kg	i.v.	1140.35 μg/L	0.48 mg·h/L	0.62 h	/	/
Rat^[5]	20 mg/kg	i.g.	64.64 μg/L	0.28 mg·h/L	5.86 h	3.38 h	10.26 %
Rat^[5]	5 mg/kg	i.v.	1393.22 μg/L	0.76 mg·h/L	0.72 h	/	/

In Vivo

Oxypeucedanin (10/15 mg/kg, i.p., once) inhibits lung inflammatory damage in a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model in a dose-dependent manner and induces the integrity of the lung air-blood barrier in mice^[3].
Oxypeucedanin (13.5 mg/kg, p.o.) alleviates the severity of collagen-induced arthritis (CIA) model in rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

LPS-induced ALI mouse model (75 male BALB/c mice, ages 6-8 weeks and weights of 20-25 g; unilateral nostril drops were added to the 50 μg LPS solution to establish the ALI model)^[3]
Dosage:

10 and 15 mg/kg
Administration:

Intraperitoneal injection (i.p.), once
Result:

Reduced lung pathological tissue damage.
Down-regulated the mRNA levels of inflammatory factors iNOS, COX-2, IL-6, IL-1β, and TNF-α.
Increased the protein levels of Occludin and Claudin 3.

Animal Model:

Rat CIA model (Male Wistar rats, subcutaneously injected with 200/100 μL emulsion that contained 2 mg/mL chicken type II collagen (HY-NP113) and complete/incomplete Freund’s adjuvant)^[4]
Dosage:

13.5 mg/kg
Administration:

Oral gavage (p.o.)
Result:

Reduced swelling, redness and bone erosions.
Increased talus volume.

Chemical Information

CAS. Nr. 737-52-0
Appearance Solid
Molecular Weight 286.28
Formel C₁₆H₁₄O₅
Color White to off-white
SMILES

CC1(C)C(O1)COC2=C(C=CO3)C3=CC(O4)=C2C=CC4=O
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
- Plants
- Umbelliferae
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 12.5 mg/mL (43.66 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4931 mL

17.4654 mL

34.9308 mL

5 mM

0.6986 mL

3.4931 mL

6.9862 mL

10 mM

0.3493 mL

1.7465 mL

3.4931 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Eun JS, et al. Effects of oxypeucedanin on hKv1.5 and action potential duration. Biol Pharm Bull. 2005 Apr;28(4):657-60. [Content Brief]

[2]. Kang TJ, et al. Anti-tumor activity of oxypeucedanin from Ostericum koreanum against human prostate carcinoma DU145 cells. Acta Oncol. 2009;48(6):895-900. [Content Brief]

[3]. Du L, et al. Oxypeucedanin relieves LPS-induced acute lung injury by inhibiting the inflammation and maintaining the integrity of the lung air-blood barrier. Aging (Albany NY). 2022 Aug 18;14(16):6626-6641. [Content Brief]

[4]. Liu M, et al. Oxypeucedanin hydrate alleviates rheumatoid arthritis by inhibiting the TLR4-MD2/NF-κB/MAPK signaling axis. Acta Biochim Biophys Sin (Shanghai). 2024 May 11;56(12):1789-1801. [Content Brief]

[5]. Zheng MC, et al. Preclinical Pharmacokinetics and Bioavailability of Oxypeucedanin in Rats after Single Intravenous and Oral Administration. Molecules. 2022 Jun 2;27(11):3570. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4931 mL	17.4654 mL	34.9308 mL	87.3271 mL
	5 mM	0.6986 mL	3.4931 mL	6.9862 mL	17.4654 mL
	10 mM	0.3493 mL	1.7465 mL	3.4931 mL	8.7327 mL
	15 mM	0.2329 mL	1.1644 mL	2.3287 mL	5.8218 mL
	20 mM	0.1747 mL	0.8733 mL	1.7465 mL	4.3664 mL
	25 mM	0.1397 mL	0.6986 mL	1.3972 mL	3.4931 mL
	30 mM	0.1164 mL	0.5822 mL	1.1644 mL	2.9109 mL
	40 mM	0.0873 mL	0.4366 mL	0.8733 mL	2.1832 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Oxypeucedanin

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Potassium Channel Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library